Rabia Gurses Ozden - 17 Mar 2022 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role
Director
Signature
Rabia Gurses Ozden, by /s/ Ron A. Metzger, Attorney-in-Fact
Issuer symbol
ADVM
Transactions as of
17 Mar 2022
Net transactions value
$0
Form type
4
Filing time
18 Mar 2022, 17:12:17 UTC
Next filing
11 Jul 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADVM Stock Option (Right to Buy) Award $0 +80,000 $0.000000 80,000 17 Mar 2022 Common Stock 80,000 $1.35 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/3 of the total number of shares subject to the option vest and become exercisable on each anniversary of March 17, 2022 (the "Vesting Commencement Date"), such that all of the shares subject to the option shall become vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.